Pancreatic Targeting Of IL-22 Therapy For Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$484,644.00
Summary
Type 2 diabetes is one of the largest problems facing health care and presents an enormous therapeutic market. Our approach with IL-22 fights the disease at the core of the problem in the pancreatic ?-cells that make insulin. Our patent focuses on targeting IL-22 to the ?-cells which promises to maximise therapeutic benefits while minimising potential adverse effects in other tissues. Independently, and in collaboration with Novo Nordisk, we are making prototype drugs to achieve this.
Development Of A Modified Gp130 Ligand To Treat Obesity-induced Insulin Resistance
Funder
National Health and Medical Research Council
Funding Amount
$438,533.00
Summary
IC7 is a mixture of two naturally occurring proteins, CNTF and IL-6. These gp130 receptor ligands have been shown to have positive metabolic effects in humans, but individually they are not suitable for therapeutic use. IC7, the novel molecule this technology is based upon, is a combination of CNTF and IL-6 in a specific design to avoid the negative effects. Preliminary results suggest that IC7 has positive metabolic effects but further development is required to increase its effectiveness in tr ....IC7 is a mixture of two naturally occurring proteins, CNTF and IL-6. These gp130 receptor ligands have been shown to have positive metabolic effects in humans, but individually they are not suitable for therapeutic use. IC7, the novel molecule this technology is based upon, is a combination of CNTF and IL-6 in a specific design to avoid the negative effects. Preliminary results suggest that IC7 has positive metabolic effects but further development is required to increase its effectiveness in treating insulin resistance and type 2 diabetes.Read moreRead less
In Vitro Diagnostic For First Trimester Risk Assignment Of Gestational Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$580,983.00
Summary
Pregnancy associated diabetes is a significant complication of pregnancy that has adverse health effects for both mother and baby. We have developed a multivariate algorithm to identify women during their first trimester of pregnancy who will subsequently develop gestational diabetes. The test requires further clinical validation to develop a commercial product and to implement it into clinical practice.
A portable device that can measure glycosylated haemoglobin (HbA1c) in the home will be developed. HbA1c is an important biomarker of the average blood glucose levels over the preceding three months and hence guides a diabetic regarding their blood glucose treatment regime. A 1% decrease in HbA1c levels is associated with a dramatic decrease in chronic health complications from diabetes. The HbA1c meter that will be developed will be able to operate with existing glucose meter technologies.
Harnessing Anticalin Technology As A Multi-targeted Treament Approach For Vision Loss
Funder
National Health and Medical Research Council
Funding Amount
$627,273.00
Summary
Diabetes is a leading cause of vision loss and blindness worldwide and is caused by two factors called VEGF and Ang2, which damage blood vessels. Current treatments only block VEGF and many patients do not respond and suffer irreversible damage to sight. We have used ground-breaking anticalin technology to make a new drug (PRS-AUS1) that blocks both VEGF and Ang2. Studies will be performed in animal models and move to patients where we expect improved outcomes compared to current treatments.